C. van Herpen

1.1k total citations · 1 hit paper
28 papers, 669 citations indexed

About

C. van Herpen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, C. van Herpen has authored 28 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Otorhinolaryngology. Recurrent topics in C. van Herpen's work include Head and Neck Cancer Studies (9 papers), Salivary Gland Tumors Diagnosis and Treatment (5 papers) and Renal cell carcinoma treatment (3 papers). C. van Herpen is often cited by papers focused on Head and Neck Cancer Studies (9 papers), Salivary Gland Tumors Diagnosis and Treatment (5 papers) and Renal cell carcinoma treatment (3 papers). C. van Herpen collaborates with scholars based in Netherlands, Belgium and France. C. van Herpen's co-authors include José A. Hardillo, Ludi E. Smeele, Annalisa Trama, B. Baujat, Ana Castro, Ester Orlandi, Anthony T.�C. Chan, M. Degardin, Lisa Licitra and Edwin P. Hui and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

C. van Herpen

25 papers receiving 662 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2020 240 citations Paolo Bossi, Anthony T.�C. Chan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. van Herpen Netherlands	12	375	325	315	177	134	28	669
J.M. del Campo Spain	10	182 0.5×	155 0.5×	373 1.2×	217 1.2×	211 1.6×	17	639
Zhien Feng China	19	538 1.4×	441 1.4×	414 1.3×	141 0.8×	290 2.2×	79	1.0k
Li‐Yu Lee Taiwan	14	288 0.8×	263 0.8×	208 0.7×	136 0.8×	266 2.0×	15	780
Albiruni Abdul Razak Canada	12	140 0.4×	132 0.4×	425 1.3×	267 1.5×	138 1.0×	37	726
Yi‐Jun Hua China	14	516 1.4×	404 1.2×	383 1.2×	344 1.9×	214 1.6×	34	971
Furhan Yunus United States	10	192 0.5×	142 0.4×	374 1.2×	306 1.7×	148 1.1×	13	658
A. J. M. Balm Netherlands	11	176 0.5×	113 0.3×	416 1.3×	175 1.0×	279 2.1×	22	720
Fulvia Pedani Italy	16	230 0.6×	511 1.6×	522 1.7×	164 0.9×	82 0.6×	42	871
Yong Bao China	16	178 0.5×	223 0.7×	316 1.0×	318 1.8×	245 1.8×	60	780
N. Al-Rajhi Saudi Arabia	6	220 0.6×	150 0.5×	215 0.7×	73 0.4×	60 0.4×	10	484

Countries citing papers authored by C. van Herpen

Since Specialization

Citations

This map shows the geographic impact of C. van Herpen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. van Herpen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. van Herpen more than expected).

Fields of papers citing papers by C. van Herpen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. van Herpen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. van Herpen. The network helps show where C. van Herpen may publish in the future.

Co-authorship network of co-authors of C. van Herpen

This figure shows the co-authorship network connecting the top 25 collaborators of C. van Herpen. A scholar is included among the top collaborators of C. van Herpen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. van Herpen. C. van Herpen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tourneau, C. Le, C. Even, Assuntina G. Sacco, et al.. (2024). 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial. Annals of Oncology. 35. S1557–S1558. 2 indexed citations

Perera, Tim, Peter de Bruijn, Rachel Galot, et al.. (2024). 143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study. European Journal of Cancer. 211. 114665–114665. 1 indexed citations

Herpen, C. van, Vincent Vander Poorten, Alena Skálová, et al.. (2022). Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 7(6). 100602–100602. 84 indexed citations

Bossi, Paolo, Anthony T.�C. Chan, Lisa Licitra, et al.. (2020). Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 32(4). 452–465. 240 indexed citations breakdown →

Ponce, Santiago, Shiven B. Patel, C. van Herpen, et al.. (2019). P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S405–S406. 1 indexed citations

Voest, Emile E., Daphne van der Velden, Louisa R. Hoes, et al.. (2019). Drug Rediscovery Protocol: Expanded use of existing anticancer drugs. Annals of Oncology. 30. v864–v865. 1 indexed citations

Voest, Emile E., Daphne van der Velden, Louisa R. Hoes, et al.. (2017). Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP). Annals of Oncology. 28. x1–x1.

Chu, Quincy S., C. van Herpen, Natasha B. Leighl, et al.. (2017). Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. 28. v539–v539. 5 indexed citations

Willemsen, Annelieke E.C.A.B., C. van Herpen, T Schneider, et al.. (2016). The influence of old age on everolimus exposure in patients with cancer. Annals of Oncology. 27. vi81–vi81.

10.

Driessen, C.M.L., A.F.M. Snik, Jan Paul de Boer, et al.. (2016). Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT). Annals of Oncology. 27. vi341–vi341.

11.

Herpen, C. van, Sanjiv S. Agarwala, Axel Hauschild, et al.. (2014). Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma. Annals of Oncology. 25. v1–v1. 14 indexed citations

12.

Franceschi, Enrico, Roger Stupp, Martin J. van den Bent, et al.. (2012). EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology. 14(12). 1503–1510. 49 indexed citations

13.

Vermorken, J. B., Éva Remenár, C. van Herpen, et al.. (2011). Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 29(15_suppl). 5530–5530. 14 indexed citations

14.

Liberatoscioli, C., Johannes A. Langendijk, C. van Herpen, et al.. (2011). EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.. Journal of Clinical Oncology. 29(15_suppl). TPS197–TPS197. 3 indexed citations

15.

Desar, Ingrid M.E., Thomas Hambrock, Edwin E. G. W. ter Voert, et al.. (2010). Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T).. Journal of Clinical Oncology. 28(15_suppl). 3051–3051. 6 indexed citations

16.

Herpen, C. van, Joachim Drevs, Hester van Cruijsen, et al.. (2007). Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. Journal of Clinical Oncology. 25(18_suppl). 3560–3560. 10 indexed citations

17.

Herpen, C. van, et al.. (2006). CMR 2005: 14.04: Oral manganese as contrast medium in detecting liver metastases with MR imaging at 1.5 and 3 T. Contrast Media & Molecular Imaging. 1(2). 90–91. 1 indexed citations

18.

Bernier, J., Corneel Coens, Éva Remenár, et al.. (2006). Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971. Journal of Clinical Oncology. 24(18_suppl). 5522–5522. 15 indexed citations

19.

Schrijvers, D., C. van Herpen, Joseph Kerger, et al.. (2004). Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Annals of Oncology. 15(4). 638–645. 60 indexed citations

20.

Vermorken, Jan B., Éva Remenár, C. van Herpen, et al.. (2004). Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Journal of Clinical Oncology. 22(14_suppl). 5508–5508. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact